https://www.pcctc.org/news daily 0.75 2026-03-25 https://www.pcctc.org/news/first-quadruplet-therapy-regimen-shows-promise-for-men-with-high-volume-metastatic-apmn-prostate-cancer monthly 0.5 2026-03-25 https://www.pcctc.org/news/dr-sean-mcbride-on-the-pcctc-managed-aasur-trial-in-high-risk-prostate-cancer monthly 0.5 2026-03-16 https://www.pcctc.org/news/advancing-the-standard-how-the-pcctc-led-the-science-at-the-2026-asco-gu-symposium-and-forged-new-paths-for-collaboration monthly 0.5 2026-03-11 https://www.pcctc.org/news/prostate-cancer-working-group-4-publishes-landmark-recommendations-in-the-journal-of-clinical-oncology monthly 0.5 2026-02-26 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/1ee093cf-61e7-4434-a1f2-4111c9bab318/PCWG4+States+Model.png News - Prostate Cancer Working Group 4 Publishes Landmark Recommendations in the Journal of Clinical Oncology - Make it stand out The PCWG4 prostate cancer clinical state model, a framework for patient treatment and drug development, updated for Prostate Cancer Clinical Trials Working Group 4. Combination therapy is considered one line of therapy. Androgen pathway modulation includes ADT and ARPI. Within each state, specify where relevant: (1) genotype (germline, somatic), (2) imaging modality used to define metastasis (PET, CT/MRI/bone scan), (3) disease characteristics and biomarkers critical for risk stratification, including pathology and immunohistochemistry, and (4) previous therapies and outcome including lack of exposure (treatment-naïve), exposed but not resistant, and resistant. APMN/S is the preferred term for hormone-/castration-naïve/castration-sensitive disease (HSPC, CSPC), whereas APMR is the preferred term for castration-/hormone-resistant prostate cancer (CRPC/HRPC). Mapping of previous PCWG3 disease states to the current PCWG4 state model is shown in Appendix Table A1. ADT, androgen deprivation therapy; APMN/S, androgen pathway modulation–naïve/sensitive; APMR, androgen pathway modulator–resistant; ARPI, androgen receptor pathway inhibitor; CSPC, castration-sensitive prostate cancer; CT, computed tomography; HSPC, hormone-sensitive prostate cancer; MRI, magnetic resonance imaging; PCWG, Prostate Cancer Clinical Trials Working Group; PET, positron emission tomography. https://www.pcctc.org/news/landmark-prostate-cancer-trial-shows-combination-therapy-more-than-doubles-survival-in-metastatic-castration-resistant-prostate-cancer-patients-with-dna-repair-defects monthly 0.5 2026-02-24 https://www.pcctc.org/news/prostate-cancer-working-group-4-unveils-updated-global-standards-for-advanced-prostate-cancer-clinical-trials-at-2026-asco-gu-symposium monthly 0.5 2026-02-23 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/d7f61f0e-eb3f-443b-ba34-28b88977ee26/PCCTClogoCOLOR.png News - Prostate Cancer Working Group 4 Unveils Updated Global Standards for Advanced Prostate Cancer Clinical Trials at 2026 ASCO GU Symposium - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.pcctc.org/news/pcctc-investigators-showcase-groundbreaking-research-at-2026-asco-gu-symposium monthly 0.5 2026-02-20 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/b5cc0749-316d-4233-8de7-cbf1113daaec/PCCTClogo_transparency.gif News - PCCTC Investigators Showcase Groundbreaking Research at 2026 ASCO GU Symposium - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.pcctc.org/news/k36-therapeutics-completes-dosing-of-first-cohort-in-pcctc-managed-phase-1-clinical-trial-of-ktx-2001-in-prostate-cancer monthly 0.5 2026-02-05 https://www.pcctc.org/news/pcctc-investigators-and-colleagues-highlight-the-importance-of-racial-diversity-in-future-genomic-profiling-and-clinical-trials-efforts-nature monthly 0.5 2026-01-29 https://www.pcctc.org/news/xtuwfplfpdk6vtzc0w21azsourjv3w monthly 0.5 2026-01-29 https://www.pcctc.org/news/2026-summer-internship-program monthly 0.5 2025-11-10 https://www.pcctc.org/news/pcctc-innovation-featured-at-biocom-californias-innovations-in-oncology-clinical-trial-design-forum monthly 0.5 2025-11-06 https://www.pcctc.org/news/lej11atqrj9rsuh3s89sv1rxat999o monthly 0.5 2025-11-03 https://www.pcctc.org/news/the-pcctcs-study-of-talazoparib-with-or-without-enzalutamide-in-people-with-prostate-cancer-who-have-previously-received-abiraterone-acetate-talent-activated monthly 0.5 2025-10-24 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/d6881033-00e3-4afa-a3e4-2409adb6de07/TALENT.png News - The PCCTC’s Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate (TALENT) Activated - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.pcctc.org/news/pcctc-managed-phase-1-study-of-k36s-novel-nsd2-inhibitor-ktx-2001-activated monthly 0.5 2025-10-14 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/b7f73853-f411-4249-88a9-0bc4c4efc00b/STRIKE+Site+activated.jpg News - PCCTC-managed Phase 1 Study of K36’s Novel NSD2 Inhibitor KTX-2001 Activated - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.pcctc.org/news/results-from-cohorts-4-and-5-of-the-phase-2-keynote-199-study-published monthly 0.5 2025-06-30 https://www.pcctc.org/news/prognostic-significance-of-psagt02-after-6-12-months-treatment-for-mhspc-intensified-by-arpis-a-multinational-real-world-analysis-of-the-ironman-registry monthly 0.5 2025-06-26 https://www.pcctc.org/news/the-pcctc-at-asco-2025 monthly 0.5 2025-05-22 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/1747947735965-6483QSGO2BXPNDHIQBRS/Slide1.PNG News - The PCCTC at ASCO 2025 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/1747947736069-RFURF1P8I7XZSYZ2TFHQ/Slide2.PNG News - The PCCTC at ASCO 2025 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/1747947749264-VMG6P9OEM9Q9CQMR5RWT/Slide1.PNG News - The PCCTC at ASCO 2025 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/1747947749381-HPANJ7ICPRG21SEG7XUC/Slide2.PNG News - The PCCTC at ASCO 2025 https://www.pcctc.org/news/dr-howard-i-scher-honored-with-richard-d-williams-md-prostate-cancer-research-excellence-award monthly 0.5 2025-04-25 https://www.pcctc.org/news/the-pcctc-at-ses-aua-2025-phase-1-trial-of-mevrometostat-pf-06821497-a-potent-and-selective-inhibitor-of-ezh2-in-crpc monthly 0.5 2025-03-17 https://www.pcctc.org/news/the-pcctc-at-asco-gu-2025 monthly 0.5 2025-02-07 https://www.pcctc.org/news/summer-internships-announced monthly 0.5 2024-12-24 https://www.pcctc.org/news/cdmrp-features-pcctc-managed-promise-registry monthly 0.5 2024-09-24 https://www.pcctc.org/news/esmo-2024-cc-94676-pca-001-clinical-activity-of-bms-986365-a-dual-androgen-receptor-ligand-directed-degrader-and-antagonist-in-heavily-pretreated-patients-with-mcrpc monthly 0.5 2024-09-17 https://www.pcctc.org/news/g46w73q8mx5oy5ql00h9njfkp166fn monthly 0.5 2024-09-11 https://www.pcctc.org/news/6th-annual-nyc-prostate-cancer-summit-to-feature-pcctc-investigators monthly 0.5 2024-09-04 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/79e8a454-62f8-4b4b-a5e0-ae600d6464bd/ProstateFlyer_2024_FINAL.jpg News - 6th Annual NYC Prostate Cancer Summit to Feature PCCTC Investigators - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.pcctc.org/news/the-prostate-cancer-clinical-trials-consortium-pcctc-receives-gift-from-friends-and-family-against-prostate-cancer monthly 0.5 2024-08-26 https://www.pcctc.org/news/results-from-the-pcctc-managed-abiraterone-olaparib-or-abiraterone-olaparib-in-first-line-mcrpc-with-dna-repair-defects-brcaaway-study-published-in-clinical-cancer-research monthly 0.5 2024-08-08 https://www.pcctc.org/news/acs-trial-library monthly 0.5 2024-07-24 https://www.pcctc.org/news/pcctc-investigator-dr-rana-mckay-wins-the-2024-christopher-g-wood-rising-star-award-at-ikcs-europe monthly 0.5 2024-07-24 https://www.pcctc.org/news/oncoc4-announces-first-patient-with-advanced-prostate-cancer-dosed-in-phase-12-trial-of-biontech-partnered-bnt316onc-392-program monthly 0.5 2024-07-24 https://www.pcctc.org/news/the-pcctc-managed-ironman-registry-deepens-the-understanding-of-racial-disparities-in-pain-and-survival-in-individuals-with-advanced-prostate-cancer monthly 0.5 2024-07-24 https://www.pcctc.org/news/the-pcctc-managed-promise-registry-manuscript-published-in-the-prostate monthly 0.5 2024-07-24 https://www.pcctc.org/news/pcctc-scientific-oversight-committee-chair-reflects-on-advances-made-in-high-risk-low-grade-prostate-cancer-management monthly 0.5 2024-07-24 https://www.pcctc.org/news/results-from-the-pcctcs-stream-study-led-by-rhonda-l-bitting-md-of-duke-university-published monthly 0.5 2024-07-24 https://www.pcctc.org/news/results-from-the-pcctcs-randomized-phase-2-trial-of-abiraterone-acetate-with-or-without-cabazitaxel-published-in-the-journal-of-clinical-oncology monthly 0.5 2024-07-24 https://www.pcctc.org/news/caris-life-sciences-pcctc-and-sorrento-therapeutics-announce-collaboration-to-advance-precision-medicine-development-using-comprehensive-genomic-profiling monthly 0.5 2024-07-24 https://www.pcctc.org/news/lantheus-collaborates-with-the-pcctc-to-advance-ai-enabled-imaging-biomarkers-in-prostate-cancer monthly 0.5 2024-07-24 https://www.pcctc.org/news/pcctc-trial-is-first-to-use-standard-ra-223-doses-contemporary-pain-endpoints-and-pro-collection-tools monthly 0.5 2024-07-24 https://www.pcctc.org/news/tackling-diversity-in-prostate-cancer-clinical-trials-a-report-from-the-diversity-working-group-of-the-ironman-registry monthly 0.5 2024-07-24 https://www.pcctc.org/news/the-pcctc-germline-genetics-working-group-publishes-new-guidelines monthly 0.5 2024-07-24 https://www.pcctc.org/news/pcctc-investigators-on-the-diversity-of-enrollment-in-prostate-cancer-clinical-trials monthly 0.5 2024-07-24 https://www.pcctc.org/news/the-transformative-development-and-progress-of-the-pcctc monthly 0.5 2024-07-24 https://www.pcctc.org/news/cellcentric-signs-agreement-with-the-pcctc-for-phase-ii-clinical-trial-expansion-into-the-us monthly 0.5 2024-07-24 https://www.pcctc.org/home daily 1.0 2025-04-30 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/564af50d-ac26-4c00-aeba-db5c1cbd544b/PCCTC+New+Paradigm+in+Clinical+Research+Management.png https://www.pcctc.org/about daily 0.75 2026-01-13 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/68b8fbd2-9a76-4eb6-b950-cc8dc922a97f/US+Clinical+Studies.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/2f8339bb-3246-4f91-966d-d3b79dcaf8a8/FDA.jpg https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/44948cce-4e81-47b2-813c-f2e5fdf53bd3/Publications.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/4825192e-b711-4346-ada8-3e7b6a33f569/Participants.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/d50eb69b-a75b-4c30-975f-b5bd32ea4909/Vinson_2024.jpg https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/dadc93ea-0168-4edc-9d2b-921ff13bb376/Green_2024.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/04e59ebf-febc-4700-b0c0-48398561888d/Scher_2024.jpg https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/7b89e119-6655-488d-b283-7ca8614c50c2/Karlin_2024.jpg https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/ea09eca5-2d30-4aa7-a0cb-21b315efb117/Morris_2024.jpg https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/49f429f7-3aae-4d75-9442-2c33d513bd24/Allen_2024.jpg https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/d5d7ee2b-1e3b-4b85-9a2b-1b5b6b822d6c/MicrosoftTeams-image+%282%29.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/def621b1-1538-43a6-94bc-324ab4d8bdaf/Chuck+Ryan.jpg https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/f1e4c915-65df-4ea2-9984-a7d2762fa85d/Gerke_2024.jpg https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/341c302b-a3eb-46c8-9524-07019feab79f/PCCTC+Global+Map_4-2025.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/ce661a12-9961-4a8a-ada3-4c12e39d64fb/PCCTC+brochure+thumbnail.png https://www.pcctc.org/guidingprinciples daily 0.75 2024-02-09 https://www.pcctc.org/workinggroups daily 0.75 2025-04-30 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/f302aeb1-8a42-444b-930c-6945ae0f4158/Evolving+Intersection.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/d0cc0d13-4e17-4785-ae7b-40e5de3825fe/practical-considerations.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/75cf232e-da0d-45b9-a7cf-41e03aa8d920/GG+Testing_Clin+GU+Cancer.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/34ea4bc4-e53a-4a71-9aca-41f9264f2d98/Ethnic+Disparities_Urologic+Oncology.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/4fb62b7a-832b-41e2-a9db-fd944dab99cc/Disparities+in+germline_Springer+Nature.png https://www.pcctc.org/services daily 0.75 2025-09-19 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/cbcec964-f507-42df-b6f1-d1beeff20bb0/Servives+Rows.png https://www.pcctc.org/expertise daily 0.75 2025-04-30 https://www.pcctc.org/studies daily 0.75 2025-11-04 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/70f95a56-c467-479f-82de-0fb742d6b1fc/logo.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/12cd460e-e6d4-4dc2-b8c4-34745c9012be/TALENT.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/9eaccc98-f434-4f92-ad12-9c7efd35b987/cropped-Logo-FullColor.png https://www.pcctc.org/privacy daily 0.75 2025-04-28 https://www.pcctc.org/talent daily 0.75 2025-04-29 https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/12cd460e-e6d4-4dc2-b8c4-34745c9012be/TALENT.png https://images.squarespace-cdn.com/content/v1/65b17ec713153c67a7dd8d8b/b4b22c5e-10de-4444-970a-76eda7adf0bc/TALENT+Schema.png